Exploring Peptido-Nanocomposites in the Context of Amyloid Diseases

Therapeutic peptides are a major class of pharmaceutical drugs owing to their target-binding specificity as well as their versatility in inhibiting aberrant protein-protein interactions associated with human pathologies. Within the realm of amyloid diseases, the use of peptides and peptidomimetics tailor-designed to overcome amyloidogenesis has been an active research endeavor since the late 90s. In more recent years, incorporating nanoparticles for enhancing the biocirculation and delivery of peptide drugs has emerged as a frontier in nanomedicine, and nanoparticles have further demonstrated a potency against amyloid aggregation and cellular inflammation to rival strategies employing small molecules, peptides, and antibodies. Despite these efforts, however, a fundamental understanding of the chemistry, characteristics and function of peptido-nanocomposites is lacking, and a systematic analysis of such strategy for combating a range of amyloid pathogeneses is missing. Here we review the history, principles and evolving chemistry of constructing peptido-nanocomposites from bottom up and discuss their future application against amyloid diseases that debilitate a significant portion of the global population. This review concerns the design principles, working mechanisms and application of peptido-nanocomposites against amyloidosis, a hallmark of amyloid diseases.image

Automated summary

Therapeutic peptides are important drugs that specifically target abnormal protein-protein interactions associated with amyloid diseases. The use of nanoparticles in combination with peptide drugs has emerged as a promising strategy for enhancing their efficacy against amyloid aggregation and cellular inflammation. However, there is still a lack of understanding of the chemistry and function of peptido-nanocomposites, and a systematic analysis of their application against a range of amyloid pathogeneses is missing.